Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?

Monteiro-Maia, Renata; Pinho, Rosa Teixeira de

doi:10.1590/0074-0276140091

Cited by 30 publications

(14 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since M.tb primarily infects the lung, matching the route of infection to the route of vaccination might be a more effective approach when developing TB vaccines. The oral route might be more efficient as a boost to a prior respiratory or systemic vaccination [75].…”

Section: Bcg and Attenuated Whole-cell Live Vaccinesmentioning

confidence: 99%

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Stylianou

Paul

Reljić

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could be achieved. The route of entry of Mycobacterium tuberculosis, the causative organism, is via inhalation making TB primarily a respiratory disease. There is therefore good reason to hypothesize that a mucosally delivered vaccine against TB could be more effective than one delivered via the systemic route. Areas covered: This review summarizes the progress that has been made in the area of TB mucosal vaccines in the last few years. It highlights some of the strengths and shortcomings of the published evidence and aims to discuss immunological and practical considerations in the development of mucosal vaccines. Expert opinion: There is a growing body of evidence that the mucosal approach to vaccination against TB is feasible and should be pursued. However, further key studies are necessary to both improve our understanding of the protective immune mechanisms operating in the mucosa and the technical aspects of aerosolized delivery, before such a vaccine could become a feasible, deployable strategy.

show abstract

Section: Bcg and Attenuated Whole-cell Live Vaccinesmentioning

confidence: 99%

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Stylianou

Paul

Reljić

et al. 2019

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…However, one of the shortcomings of s.c. BCG administration is the overall weak memory lymphocyte generation, which in addition lacks the mucosal-homing chemokine receptors that allow migration to the lung (9). Hence, mucosal vaccination has been suggested as a mimic of natural infection in order to improve local immunity at the site of infection (10–12). Comprehensive analyses of local immunity and correlates of protection in both the lung airways and the parenchyma are essential for the rational design of mucosal TB vaccination strategies using BCG (13, 14).…”

Section: Introductionmentioning

confidence: 99%

Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis

Perdomo

Zedler

Kühl

et al. 2016

mBio

205

228

View full text Add to dashboard Cite

Mycobacterium bovis Bacille Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB), yet its moderate efficacy against pulmonary TB calls for improved vaccination strategies. Mucosal BCG vaccination generates superior protection against TB in animal models; however, the mechanisms of protection remain elusive. Tissue-resident memory T (TRM) cells have been implicated in protective immune responses against viral infections, but the role of TRM cells following mycobacterial infection is unknown. Using a mouse model of TB, we compared protection and lung cellular infiltrates of parenteral and mucosal BCG vaccination. Adoptive transfer and gene expression analyses of lung airway cells were performed to determine the protective capacities and phenotypes of different memory T cell subsets. In comparison to subcutaneous vaccination, intratracheal and intranasal BCG vaccination generated T effector memory and TRM cells in the lung, as defined by surface marker phenotype. Adoptive mucosal transfer of these airway-resident memory T cells into naive mice mediated protection against TB. Whereas airway-resident memory CD4+ T cells displayed a mixture of effector and regulatory phenotype, airway-resident memory CD8+ T cells displayed prototypical TRM features. Our data demonstrate a key role for mucosal vaccination-induced airway-resident T cells in the host defense against pulmonary TB. These results have direct implications for the design of refined vaccination strategies.

show abstract

“…Recent studies show a resurgence of interest in the oral administration of BCG; at one time, it was abandoned in favor of the subcutaneous due to the contamination of the vaccine with TB in Lübeck. However, some data demonstrate an increase in protective efficacy if oral administration is used together with traditional subcutaneous vaccination [ 68 , 69 ].…”

Section: Introductionmentioning

confidence: 99%

Vaccines Against Tuberculosis: Problems and Prospects (Review)

Nadolinskaia

Карпов

Гончаренко

2020

Appl Biochem Microbiol

View full text Add to dashboard Cite

Despite the efforts of the global medical and scientific community, tuberculosis remains the leading cause of death from infectious diseases. The expectation of success associated with the development of new anti-TB drugs was not justified, and the attention of researchers was largely drawn to the creation of new mycobacterial strains for vaccination against tuberculosis. The proposed review contains current information on the existing vaccine strains and the development of new, genetically engineered strains for the prevention of tuberculosis and the prevention and treatment of other diseases. The review includes relevant information on the correlation between BCG vaccination and the frequency and severity of COVID-19 infection.

show abstract

Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?

Cited by 30 publications

References 55 publications

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges

Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis

Vaccines Against Tuberculosis: Problems and Prospects (Review)

Contact Info

Product

Resources

About